ClinicalTrials.gg
CompletedNCT01283711Updated May 17, 2013

Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides

An interventional study of apollo device in Facelift, sponsored by Pollogen. Completed at 2 sites in 2 countries. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-17.

Sponsored by Pollogen (part of Lumenis Be Ltd.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Study summary

Non-invasive, energy-based, aesthetic treatments are becoming increasingly popular among female and male patients of all ages. Different technologies are presently available to rejuvenate skin, including therapeutic ultrasound, lasers and intense pulsed light (IPL), however radiofrequency has emerged as the most effective and versatile modality for the broadest range of body and facial treatments, including non-invasive wrinkle treatment.

The apollo™ system is an RF system, based on the TriPollar™ technology. The technology is based on three or more electrodes designed to deliver RF current focused into the skin, thus generating heat in the dermal layer. Selective and focused electro-heating of the skin is intended to stimulate collagen remodeling in the dermal layer resulting in non invasive wrinkle treatment.

The apollo™ system is intended for use in dermatologic and general surgical procedures for non invasive treatment of facial wrinkles and rhytides. This study was designed in order to evaluate the safety and efficacy of the Apollo™ System for facial wrinkles and rhytides treatments.

02

Conditions studied

  • Facelift

Keywords

  • wrinkles reduction
  • rhytides reduction
  • RF treatment
03

In context

Lead sponsor

Pollogen is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted before Pollogen became part of Lumenis Be Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject read, understood and signed the Consent Form
  • Healthy female/male aged 35 65 years,
  • Fitzpatrick wrinkle classification score 4 and above
  • Subject is capable of reading, understanding and following instructions of the procedure to be applied.
  • Subject is able and willing to comply with the treatment and follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  • Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
  • Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
  • Subject has current or history of cancer, especially skin cancer or premalignant moles or is undergoing any form of treatment for active cancer.
  • Subject has severe concurrent conditions such as epilepsy, lupus or cardiac disorders.
  • Subject has poorly controlled endocrine disorders such as diabetes.
  • Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
  • Subject has an impaired immune system due to diseases such as or AIDS, or use of immunosuppressive medications.
  • Subject has a condition that could be negatively affected by heat, including any history of diseases stimulated by heat, such as recurrent Herpes Simplex (in the treatment area).
  • Subject has diminished or exaggerated perception of temperature changes.
  • Subject has significant concurrent skin conditions affecting areas to be treated such as sores, hemorrhages or risk of hemorrhages, septic conditions, psoriasis, eczema and rash as well as very dry and fragile skin.
  • Subject has history of collagen disorders, keloid formation and abnormal wound healing.
  • Subject has had previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans on such treatment during the course of the study, or before complete healing has occurred.
  • Subject has had Botox injections in the treatment area within 6 months prior to initial treatment
  • Subject has had natural fillers within 9 months prior to initial treatment
  • Subject has synthetic fillers or gold/plastic threads in the treatment area.
  • Subject takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing such as prolonged regime, tetracyclines, or St. John's Wort for the last 3 months.
  • Subject has used oral isotretinoin (Accutane or Roaccutan) within 6 months prior to study enrollment or plans use during the course of the study.
  • Subject has history of bleeding coagulopathies or use of anticoagulants.
  • Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
  • Concurrent participation in any other study.
  • Subject has mental disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    apollo

    Device: apollo device

Interventions

  • Deviceapollo device

    RF treatments for wrinkles and rhytides reduction

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of the apollo™ system for wrinkles and rhytides treatment.

    The safety of using the apollo™ system for wrinkles and rhytides treatment will be established by physician's assessment/observation of adverse events.

    Time frame: 5 months

Secondary outcomes

  1. • To evaluate the efficacy of the apollo™ system for wrinkles and rhytides treatment.

    Efficacy of using the apollo™ system for wrinkles and rhytides treatment will be established by level of wrinkle reduction.

    Time frame: 5 months

07

Study locations

2 sites
  • Steven D. Shapiro MD
    Palm Beach Gardens, Florida 33410, United States
  • Kaplan Medical center
    Rehovot, 76610, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2011
First posted
Jan 26, 2011
Start
Mar 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
May 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01283711
Lead sponsor
Pollogen
Responsible party
Sponsor
First posted
Jan 26, 2011
Start date
Mar 2011
Primary completion
Sep 2011
Completion
Sep 2011
Last update
May 17, 2013

Study contacts

Mira Barki, Dr.
study director · Pollogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion